← Back to Clinical Trials
Recruiting NCT05050617

NCT05050617 Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05050617
Status Recruiting
Phase
Sponsor WellSpan Health
Condition Pulmonary Embolism
Study Type OBSERVATIONAL
Enrollment 250 participants
Start Date 2021-09-09
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Point-of-care echocardiography

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 250 participants in total. It began in 2021-09-09 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is an observational, prospective study examining the role point-of-care echocardiography of predicting short term adverse outcomes in emergency department patients with acute pulmonary embolism. The primary objective is to assess the diagnostic performance of ultrasound-guided measures of right ventricular dilation (RVD) and strain in predicting clinical outcomes in acute PE. The secondary objective is to investigate the utility of combining ultrasound-guided measures of RVD and the pulmonary embolism severity index (PESI) score in predicting adverse outcomes in acute PE.

Eligibility Criteria

Inclusion Criteria: * Age \>= 18 years of age * ED diagnosis of acute pulmonary embolism with identification on CT imaging Exclusion Criteria: * Age \<18 years of age * Inability to provide informed consent * Incarceration * Current PE previously diagnosed prior to index ED visit

Contact & Investigator

Central Contact

Brent A Becker, MD

✉ bbecker2@wellspan.org

📞 717 851 4819

Principal Investigator

Brent A Becker, MD

PRINCIPAL INVESTIGATOR

WellSpan Health

Frequently Asked Questions

Who can join the NCT05050617 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Pulmonary Embolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05050617 currently recruiting?

Yes, NCT05050617 is actively recruiting participants. Contact the research team at bbecker2@wellspan.org for enrollment information.

Where is the NCT05050617 trial being conducted?

This trial is being conducted at York, United States.

Who is sponsoring the NCT05050617 clinical trial?

NCT05050617 is sponsored by WellSpan Health. The principal investigator is Brent A Becker, MD at WellSpan Health. The trial plans to enroll 250 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology